{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T20:03:31Z","timestamp":1787601811693,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002648","name":"Catholic University of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002648","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"publisher","award":["RS-2022-KH123877"],"award-info":[{"award-number":["RS-2022-KH123877"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"publisher","award":["RS-2022-KH129299"],"award-info":[{"award-number":["RS-2022-KH129299"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012413","name":"Catholic Institute of Cell Therapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012413","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["RS-2022-NR067389"],"award-info":[{"award-number":["RS-2022-NR067389"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jtct.2026.01.001","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T16:15:04Z","timestamp":1767975304000},"page":"448.e1-448.e16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cytokine-Induced Killer Cell Therapy as a Postremission Strategy in High-Risk Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Prospective Investigator-Initiated Clinical Study"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7636-4693","authenticated-orcid":false,"given":"Gi-June","family":"Min","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8317-2921","authenticated-orcid":false,"given":"Nayoun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keon-Il","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4591-4693","authenticated-orcid":false,"given":"Junseok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Jip","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5429-4839","authenticated-orcid":false,"given":"Seok-Goo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.01.001_bib0001","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","article-title":"Autologous transplantation as consolidation for aggressive non-Hodgkin\u2019s lymphoma","volume":"369","author":"Stiff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.01.001_bib0002","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3904\/kjim.2015.30.3.362","article-title":"Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients","volume":"30","author":"Yoon","year":"2015","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.jtct.2026.01.001_bib0003","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1023\/A:1015415928521","article-title":"Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice","volume":"22","author":"Verneris","year":"2002","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jtct.2026.01.001_bib0004","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1182\/blood-2011-02-336321","article-title":"Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity","volume":"118","author":"Pievani","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.01.001_bib0005","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.174.1.139","article-title":"Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity","volume":"174","author":"Schmidt-Wolf","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.jtct.2026.01.001_bib0006","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/j.bbmt.2017.07.005","article-title":"Phase II study of sequential infusion of donor lymphocyte infusion and cytokine-induced killer cells for patients relapsed after allogeneic hematopoietic stem cell transplantation","volume":"23","author":"Introna","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.01.001_bib0007","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.bbmt.2011.05.012","article-title":"Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation","volume":"17","author":"Laport","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.01.001_bib0008","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.bbmt.2019.03.027","article-title":"Donor-derived cytokine-induced killer cell infusion as consolidation after nonmyeloablative allogeneic transplantation for myeloid neoplasms","volume":"25","author":"Narayan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.01.001_bib0009","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3390\/ijms19020358","article-title":"Innovative clinical perspectives for CIK cells in cancer patients","volume":"19","author":"Introna","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtct.2026.01.001_bib0010","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.01.001_bib0011","first-page":"603","article-title":"Isolation of CD34+ hematopoietic progenitor cells in chronic myeloid leukemia by magnetic activated cell sorting (MACS)","volume":"18","author":"Mart\u00edn-Henao","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.01.001_bib0012","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12967-017-1330-5","article-title":"GMP-production of purified human B lymphocytes for the adoptive transfer in patients after allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Tittlbach","year":"2017","journal-title":"J Transl Med"},{"key":"10.1016\/j.jtct.2026.01.001_bib0013","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/sj.bmt.1704110","article-title":"Autologous stem cell transplantation for Hodgkin\u2019s disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen","volume":"32","author":"Gutierrez-Delgado","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.01.001_bib0014","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s41409-018-0289-z","article-title":"Autologous hematopoietic cell transplantation using dose-reduced intravenous busulfan, melphalan, and thiotepa for high-risk or relapsed lymphomas","volume":"54","author":"Yoon","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.01.001_bib0015","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0022-1759(02)00167-9","article-title":"A flow-cytometry based cytotoxicity assay using stained effector cells in combination with native target cells","volume":"267","author":"H\u00f6ppner","year":"2002","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jtct.2026.01.001_bib0016","doi-asserted-by":"crossref","first-page":"9291","DOI":"10.1002\/jcp.29827","article-title":"Ten-year update of the international registry on cytokine-induced killer cells in cancer immunotherapy","volume":"235","author":"Zhang","year":"2020","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jtct.2026.01.001_bib0017","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s13287-024-03869-z","article-title":"Cytokine-induced killer cells: new insights for therapy of hematologic malignancies","volume":"15","author":"Ghanbari Sevari","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jtct.2026.01.001_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3960\/jslrt.22034","article-title":"Prognostic indices for peripheral T-cell lymphoma\u2014not otherwise specified and adult T-cell leukemia\/lymphoma: from past to future","volume":"63","author":"Ishitsuka","year":"2023","journal-title":"J Clin Exp Hematop"},{"key":"10.1016\/j.jtct.2026.01.001_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1388623","article-title":"Hematopoietic stem cell transplantation to improve prognosis in aggressive monomorphic epitheliotropic intestinal T-cell lymphoma","volume":"14","author":"Min","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2026.01.001_bib0020","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/ajh.23213","article-title":"Type II enteropathy-associated T-cell lymphoma: a multicenter analysis from the Asia Lymphoma Study Group","volume":"87","author":"Tse","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2026.01.001_bib0021","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the international peripheral T-cell lymphoma project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.01.001_bib0022","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.01.001_bib0023","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.01.001_bib0024","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood.2020010387","article-title":"Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell project","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.01.001_bib0025","doi-asserted-by":"crossref","first-page":"7091","DOI":"10.1007\/s00432-023-04660-y","article-title":"Survival outcomes of patients newly diagnosed with diffuse large B-cell lymphoma: real-world evidence from a German claims database","volume":"149","author":"Borchmann","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jtct.2026.01.001_bib0026","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.01.001_bib0027","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.01.001_bib0028","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa031770","article-title":"Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support","volume":"350","author":"Milpied","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.01.001_bib0029","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2002.02.125","article-title":"Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma","volume":"20","author":"Gisselbrecht","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.01.001_bib0030","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1200\/JCO.2003.01.117","article-title":"Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin\u2019s lymphoma: an Italian multicenter randomized trial","volume":"21","author":"Martelli","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.01.001_bib0031","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1200\/JCO.2002.07.075","article-title":"Randomized study to evaluate the use of high-dose therapy as part of primary treatment for \"aggressive\" lymphoma","volume":"20","author":"Kaiser","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.01.001_bib0032","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.01.001_bib0033","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.01.001_bib0034","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.01.001_bib0035","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1182\/blood-2021-147499","article-title":"Outcomes of cytomegalovirus monitoring in autologous transplantation: a single institution experience","volume":"138","author":"Fesler","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.01.001_bib0036","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00277-016-2700-4","article-title":"Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab","volume":"95","author":"Jain","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2026.01.001_bib0037","doi-asserted-by":"crossref","first-page":"17230","DOI":"10.18632\/oncotarget.7347","article-title":"Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission","volume":"7","author":"Yoon","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtct.2026.01.001_bib0038","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3346\/jkms.2009.24.4.571","article-title":"Comparison of quantitative cytomegalovirus real-time PCR in whole blood and pp65 antigenemia assay: clinical utility of CMV real-time PCR in hematopoietic stem cell transplant recipients","volume":"24","author":"Choi","year":"2009","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.jtct.2026.01.001_bib0039","article-title":"NKG2D engagement alone is sufficient to activate cytokine-induced killer cells while 2B4 only provides limited coactivation","volume":"12","author":"Wu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2026.01.001_bib0040","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2007-06-092817","article-title":"In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity","volume":"112","author":"Nishimura","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.01.001_bib0041","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.biopha.2014.04.004","article-title":"Modification of chemokine receptor expression to enhance levels of trafficking receptors on autologous cytokine-induced killer cells derived from patients with colorectal cancer","volume":"68","author":"Wang","year":"2014","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jtct.2026.01.001_bib0042","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/blood-2002-06-1751","article-title":"Negrin RS. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging","volume":"101","author":"Edinger","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.01.001_bib0043","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/stem.769","article-title":"Concise review: cancer stem cells and minimal residual disease","volume":"30","author":"Ghiaur","year":"2012","journal-title":"Stem Cells"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726000035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726000035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T19:34:19Z","timestamp":1778355259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726000035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2666636726000035"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.01.001","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokine-Induced Killer Cell Therapy as a Postremission Strategy in High-Risk Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Prospective Investigator-Initiated Clinical Study","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}